RapidAI Secures Clearance for Angioflow Perfusion Imaging Analysis Software for Stroke Assessment

RapidAI (Menlo Park, CA), a developer of clinical decision support and patient workflow solutions using artificial intelligence for neurovascular and vascular care, announced that the Food and Drug Administration (FDA) has granted 510(k) clearance for its AngioFlow solution. AngioFlow is designed to deliver perfusion imaging analysis directly within the interventional suite, helping to promote greater clinical confidence, workflow efficiency, and potentially improved patient outcomes for the treatment of patients experiencing stroke. 

The system analyzes CT, CTA, MRI, and MRA images to assist in the following applications:   

• Selection of acute stroke patients for endovascular thrombectomy
• Volumetry of thresholded maps
• Time intensity plots for dynamic time courses
• Measurement of mismatch between labeled volumes on co-registered image volumes
• Large vessel density

"AngioFlow by RapidAI will allow physicians to assess the need for additional imaging immediately in the interventional suite. By avoiding unnecessary scans, stroke patients can receive the timely care that can be the difference between being able to walk out of a hospital to their homes versus being discharged to a skilled nursing facility," said Abhishek Singh, MD, Assistant Professor, Creighton University School of Medicine.